Vertex Pharmaceuticals Share Price (NASDAQ: VRTX)

$393.01

▲

3.13

(0.8%)

Live

Last updated on August 20, 2025 at 1:29 AM IST

$₹

Check the interactive Vertex Pharmaceuticals Stock chart to analyse performance

Vertex Pharmaceuticals stock performance

as on August 20, 2025 at 1:29 AM IST

Today's Low:$389.85
Today's High:$395.40
$393.01
0.8%
Downside
Day's Volatility :1.4%
Upside
0.6%
52 Weeks Low:$362.50
52 Weeks High:$519.88
$393.01
7.76%
Downside
52 Weeks Volatility :30.27%
Upside
24.4%

Vertex Pharmaceuticals Stock Returns

Period	Vertex Pharmaceuticals Incorporated	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-12.82%	1.1%	12.6%
6 Months	-15.63%	-7.2%	7.8%
1 Year	-20.12%	-11.6%	21.0%
3 Years	32.68%	2.2%	70.2%

Vertex Pharmaceuticals Incorporated Key Stats

Check Vertex Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$389.88
Open	$393.61
Today's High	$395.4
Today's Low	$389.85
Market Capitalization	$100.7B
Today's Volume	$1.4M
52 Week High	$519.88
52 Week Low	$362.5
Revenue TTM	$11.4B
EBITDA	$4.8B
Earnings Per Share (EPS)	$14.06
PE Ratio	27.94
Profit Margin	31.86%
Quarterly Earnings Growth YOY	-0.41%
Return On Equity TTM	22.77%

Stock Returns calculator for Vertex Pharmaceuticals Stock including INR - Dollar returns

The Vertex Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Vertex Pharmaceuticals investment value today

Current value as on today

₹84,151

Returns

₹15,849

(-15.85%)

Returns from Vertex Pharmaceuticals Stock

₹19,473 (-19.47%)

Dollar Returns*

₹3,624 (+3.62%)

Indian investors sentiment towards Vertex Pharmaceuticals Stock

118.67%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Investment in Vertex Pharmaceuticals Shares from India has grown by 118.67% over the past 30 days, indicating increased transactional activity.

57%

Period: Jul 19, 2025 to Aug 18, 2025. Change in 30 Days versus previous period

Search interest for Vertex Pharmaceuticals Stock from India on INDmoney has increased by 57% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Vertex Pharmaceuticals Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	2076	34.38	0.22%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	3655	111.66	0.67%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	404	0.00	0.98%

Global Institutional Holdings in Vertex Pharmaceuticals Incorporated

Name
Holdings %
Name
Holdings %
Capital World Investors
11.21%
Vanguard Group Inc
9.35%
BlackRock Inc
8.50%
Capital Research Global Investors
6.28%
State Street Corp
4.60%
JPMorgan Chase & Co
3.02%

Analyst Recommendation on Vertex Pharmaceuticals Stock

Rating

Trend

Buy

68%Buy

26%Hold

5%Sell

Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals(by analysts ranked 0 to 5 stars)

Vertex Pharmaceuticals Share Price Target

What analysts predicted

Upside of 22.7%

Target:

$482.24

Current:

$393.01

Vertex Pharmaceuticals share price target is $482.24, a slight Upside of 22.7% compared to current price of $393.01 as per analysts' prediction.

Vertex Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, VRTX stock has moved down by -15.2%
Increasing Revenue
Vertex Pharmaceuticals Incorporated has shown a positive revenue trend over the last two quarters. In the most recent quarter, the revenue increased to $2.96 billion, up from $2.77 billion in the previous quarter. This represents an average increase of 6.6% in revenue each quarter.
Increasing Net Profit
Vertex Pharmaceuticals Incorporated has shown a positive trend in its net profit over the last two quarters. The net profit increased from $646.3 million to $1.03 billion, reflecting an average increase of 37.4% per quarter.
VRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.4% return, outperforming this stock by 86.5%
VRTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 81.1%
Price to Sales
Vertex Pharmaceuticals Incorporated has a Price-to-Sales Ratio of 8.8. This means that investors are willing to pay $8.80 for every $1 of sales that the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a much higher Price-to-Sales Ratio of 24.0, indicating that investors are willing to pay $24 for every $1 of sales for that company.

Vertex Pharmaceuticals Incorporated Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$4.2B	↑ 36.59%
Net Income	$1.2B	↓ 43.88%
Net Profit Margin	28.27%	↓ 40.53%

	FY20	Y/Y Change
Revenue	$6.2B	↑ 49.07%
Net Income	$2.7B	↑ 130.43%
Net Profit Margin	43.7%	↑ 15.43%

	FY21	Y/Y Change
Revenue	$7.6B	↑ 22.06%
Net Income	$2.3B	↓ 13.63%
Net Profit Margin	30.92%	↓ 12.78%

	FY22	Y/Y Change
Revenue	$8.9B	↑ 17.91%
Net Income	$3.3B	↑ 41.84%
Net Profit Margin	37.2%	↑ 6.28%

	FY23	Y/Y Change
Revenue	$9.9B	↑ 10.51%
Net Income	$3.6B	↑ 8.96%
Net Profit Margin	36.68%	↓ 0.52%

	FY24	Y/Y Change
Revenue	$11.0B	↑ 11.66%
Net Income	$-535.6M	↓ 114.8%
Net Profit Margin	-4.86%	↓ 41.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$2.7B	↑ 6.73%
Net Income	$1.1B	↑ 13.5%
Net Profit Margin	40.92%	↑ 2.44%

	Q2 FY24	Q/Q Change
Revenue	$2.6B	↓ 1.55%
Net Income	$-3.6B	↓ 426.81%
Net Profit Margin	-135.83%	↓ 176.75%

	Q3 FY24	Q/Q Change
Revenue	$2.8B	↑ 4.77%
Net Income	$1.0B	↓ 129.09%
Net Profit Margin	37.71%	↑ 173.54%

	Q4 FY24	Q/Q Change
Revenue	$2.9B	↑ 5.05%
Net Income	$913.0M	↓ 12.67%
Net Profit Margin	31.35%	↓ 6.36%

	Q1 FY25	Q/Q Change
Revenue	$2.8B	↓ 4.87%
Net Income	$646.3M	↓ 29.21%
Net Profit Margin	23.33%	↓ 8.02%

	Q2 FY25	Q/Q Change
Revenue	$3.0B	↑ 7.02%
Net Income	$1.0B	↑ 59.82%
Net Profit Margin	34.84%	↑ 11.51%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$3.6B	↑ 37.04%

	FY20	Y/Y Change
Profit	$5.5B	↑ 51.29%

	FY21	Y/Y Change
Profit	$6.7B	↑ 21.96%

	FY22	Y/Y Change
Profit	$7.9B	↑ 17.69%

	FY23	Y/Y Change
Profit	$8.6B	↑ 9.64%

	FY24	Y/Y Change
Profit	$9.5B	↑ 10.25%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.3B	↑ 9.07%

	Q2 FY24	Q/Q Change
Profit	$2.3B	↓ 3.02%

	Q3 FY24	Q/Q Change
Profit	$2.4B	↑ 4.64%

	Q4 FY24	Q/Q Change
Profit	$2.5B	↑ 4.59%

	Q1 FY25	Q/Q Change
Profit	$2.4B	↓ 3.27%

	Q2 FY25	Q/Q Change
Profit	$2.6B	↑ 6.23%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$1.6B	↑ 23.54%
Investing Cash Flow	$-1.2B	↑ 511.07%
Financing Cash Flow	$126.8M	↓ 278.0%

	FY20	Y/Y Change
Operating Cash Flow	$3.3B	↑ 107.32%
Investing Cash Flow	$99.4M	↓ 108.05%
Financing Cash Flow	$-505.3M	↓ 498.57%

	FY21	Y/Y Change
Operating Cash Flow	$2.6B	↓ 18.75%
Investing Cash Flow	$-340.9M	↓ 443.0%
Financing Cash Flow	$-1.5B	↑ 192.51%

	FY22	Y/Y Change
Operating Cash Flow	$4.1B	↑ 56.23%
Investing Cash Flow	$-321.1M	↓ 5.81%
Financing Cash Flow	$-67.7M	↓ 95.42%

	FY23	Y/Y Change
Operating Cash Flow	$3.5B	↓ 14.35%
Investing Cash Flow	$-3.1B	↑ 878.42%
Financing Cash Flow	$-562.2M	↑ 730.43%

	FY24	Y/Y Change
Operating Cash Flow	$-492.6M	↓ 113.93%
Investing Cash Flow	$-3.8B	↑ 20.0%
Financing Cash Flow	$-1.5B	↑ 165.9%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.3B	↑ 456.95%
Investing Cash Flow	$-2.1B	↑ 140.99%
Financing Cash Flow	$-357.5M	↑ 198.41%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-3.8B	↓ 387.28%
Investing Cash Flow	$-463.7M	↓ 78.3%
Financing Cash Flow	$-358.6M	↑ 0.31%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$1.4B	↓ 136.49%
Investing Cash Flow	$-348.0M	↓ 24.95%
Financing Cash Flow	$-387.5M	↑ 8.06%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$584.6M	↓ 57.32%
Investing Cash Flow	$-821.9M	↑ 136.18%
Financing Cash Flow	$-391.3M	↑ 0.98%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$818.9M	↑ 40.08%
Investing Cash Flow	$-55.8M	↓ 93.21%
Financing Cash Flow	$-680.4M	↑ 73.88%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$1.1B	↑ 31.04%
Investing Cash Flow	$-484.5M	↑ 768.28%
Financing Cash Flow	$-349.2M	↓ 48.68%

Vertex Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Vertex Pharmaceuticals Incorporated Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vertex Pharmaceuticals Incorporated	-14.97%	-15.63%	-20.12%	32.68%	43.64%
Regeneron Pharmaceuticals, Inc.	5.3%	-15.53%	-52.01%	-6.15%	-6.88%
Beone Medicines Ltd	9.32%	34.03%	65.78%	84.48%	35.61%
Alnylam Pharmaceuticals, Inc.	42.53%	82.74%	66.44%	109.65%	235.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	43.64%	27.94	31.86%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-6.88%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	35.61%	NA	-3.89%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.02%	NA	-12.96%

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Organization	Vertex Pharmaceuticals
Employees	6100
CEO	Dr. Reshma Kewalramani FASN, M.D.
Industry	Health Technology

Key Management of Vertex Pharmaceuticals Incorporated

Name	Title
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director
Mr. Charles F. Wagner Jr.	Executive VP, COO & CFO
Dr. David M. Altshuler M.D., Ph.D.	Executive VP & Chief Scientific Officer
Dr. Ourania Tatsis Ph.D.	Executive VP and Chief Regulatory & Quality Officer
Ms. Kristen C. Ambrose CPA	Senior VP & Chief Accounting Officer
Ms. Susie Lisa C.F.A.	Senior Vice President of Investor Relations
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer
Ms. Nina Devlin	Senior VP & Chief Communications Officer
Ms. Stephanie Franklin	Senior VP & Chief Human Resources Officer

Important FAQs about investing in VRTX Stock from India :

What is Vertex Pharmaceuticals share price today?

Vertex Pharmaceuticals share price today is $393.01 as on August 20, 2025 at 1:29 AM IST. Vertex Pharmaceuticals share today touched a day high of $395.40 and a low of $389.85.

What is the 52 week high and 52 week low for Vertex Pharmaceuticals share?

Vertex Pharmaceuticals share touched a 52 week high of $519.88 and a 52 week low of $362.50. Vertex Pharmaceuticals stock price today i.e. August 20, 2025 at 1:29 AM IST is trending at $393.01, lower by 24.4% versus the 52 week high.

How to invest in Vertex Pharmaceuticals Stock (VRTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vertex Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vertex Pharmaceuticals Shares that will get you 0.0038 shares as per Vertex Pharmaceuticals share price of $393.01 per share as on August 20, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Vertex Pharmaceuticals Stock (VRTX) from India?

Indian investors can start investing in Vertex Pharmaceuticals (VRTX) shares with as little as ₹86.938 or $1 (as of August 19, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹869.38 in Vertex Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 19, 2025). Based on Vertex Pharmaceuticals share’s latest price of $393.01 as on August 20, 2025 at 1:29 AM IST, you will get 0.0254 shares of Vertex Pharmaceuticals. Learn more about fractional shares .

What are the returns that Vertex Pharmaceuticals has given to Indian investors in the last 5 years?

Vertex Pharmaceuticals stock has given 43.64% share price returns and 16.15% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?